Literature DB >> 22525314

Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.

Oxana Ryabtsova1, Koen Jansen, Sebastiaan Van Goethem, Jurgen Joossens, Jonathan D Cheng, Anne-Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken.   

Abstract

A series of N-acylated glycyl-(2-cyano)pyrrolidines were synthesized with the aim of generating structure-activity relationship (SAR) data for this class of compounds as inhibitors of fibroblast activation protein (FAP). Specifically, the influence of (1) the choice of the N-acyl group and (2) structural modification of the 2-cyanopyrrolidine residue were investigated. The inhibitors displayed inhibitory potency in the micromolar to nanomolar range and showed good to excellent selectivity with respect to the proline selective dipeptidyl peptidases (DPPs) DPP IV, DPP9 and DPP II. Additionally, selectivity for FAP with respect to prolyl oligopeptidase (PREP) is reported. Not unexpectedly, the latter data suggest significant overlap in the pharmacophoric features that define FAP or PREP-inhibitory activity and underscore the importance of systematically evaluating the FAP/PREP-selectivity index for inhibitors of either of these two enzymes. Finally, this study forwards several compounds that can serve as leads or prototypic structures for future FAP-selective-inhibitor discovery.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525314     DOI: 10.1016/j.bmcl.2012.03.107

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

2.  FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans.

Authors:  Ricardo J Samms; Jo E Lewis; Luke Norton; Francis B Stephens; Christopher J Gaffney; Tony Butterfield; Dennis P Smith; Christine C Cheng; James W Perfield; Andrew C Adams; Francis J P Ebling; Kostas Tsintzas
Journal:  J Clin Endocrinol Metab       Date:  2017-10-01       Impact factor: 5.958

3.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

4.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.

Authors:  Stephanie L Slania; Deepankar Das; Ala Lisok; Yong Du; Zirui Jiang; Ronnie C Mease; Steven P Rowe; Sridhar Nimmagadda; Xing Yang; Martin G Pomper
Journal:  J Med Chem       Date:  2021-03-17       Impact factor: 8.039

5.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

6.  A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).

Authors:  James M Kelly; Thomas M Jeitner; Shashikanth Ponnala; Clarence Williams; Anastasia Nikolopoulou; Stephen G DiMagno; John W Babich
Journal:  Mol Imaging Biol       Date:  2021-03-15       Impact factor: 3.488

Review 7.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

8.  Fibroblast activation protein (FAP) as a novel metabolic target.

Authors:  Miguel Angel Sánchez-Garrido; Kirk M Habegger; Christoffer Clemmensen; Cassie Holleman; Timo D Müller; Diego Perez-Tilve; Pengyun Li; Archita S Agrawal; Brian Finan; Daniel J Drucker; Matthias H Tschöp; Richard D DiMarchi; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2016-07-16       Impact factor: 7.422

9.  New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.

Authors:  Raj Kumar; Rohit Bavi; Min Gi Jo; Venkatesh Arulalapperumal; Ayoung Baek; Shailima Rampogu; Myeong Ok Kim; Keun Woo Lee
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

Review 10.  Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy.

Authors:  Sofia Koustoulidou; Mark W H Hoorens; Simone U Dalm; Shweta Mahajan; Reno Debets; Yann Seimbille; Marion de Jong
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.